Classical Hodgkin LymphomaPhase 1ACTIONNCT05352828
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
A Phase 1 study testing Nivolumab, Autologous CD30.CAR-T and Fludarabine in people with Classical Hodgkin Lymphoma and Hodgkin Disease Refractory, run by Tessa Therapeutics at 5 sites in United States.
Trial summary
This is a Phase 1b, multicenter, open-label, single arm study to evaluate the safety and efficacy of the combination therapy, CD30.CAR-T and the programmed cell death protein-1 (PD-1) checkpoint inhibitor, nivolumab, in patients aged 12 years of age and above with relapsed or refractory classical Hodgkin lymphoma… Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
- What is being tested?
- Nivolumab, Autologous CD30.CAR-T and Fludarabine
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 5 sitesUnited States
- Study dates
- 25 Jul 2022to 15 Dec 2037
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Signed ICF
- Male or female patients who are 12 years of age and above
- Relapsed or refractory CD30+ cHL following failure of a standard frontline chemotherapy
- At least 1 lesion, which must be fluordeoxyglucose positron emission tomography (FDG-PET) avid and measurable by PET-CT scan
- Adequate laboratory parameters including hematologic, renal, hepatic, and coagulation function
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, or equivalent either Karnofsky performance status (for patients ≥ 16 years of age) or Lansky performance status (for patients < 16 years of age)
- Anticipated life expectancy > 12 weeks
- No active infections including COVID 19 at Screening
Who cannot join
- Evidence of lymphomatous involvement of the central nervous system (CNS)
- Presence of clinically relevant or active seizure disorder, stroke, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with central nervous system (CNS) involvement
- Symptomatic cardiovascular disease: Class III or IV according to the New York Heart Association (NYHA) Functional Classification
- Active uncontrolled bleeding or a known bleeding diathesis
- Inadequate pulmonary function defined as oxygen saturation by pulse oximetry < 90% on room air
- Echocardiogram (ECHO) or Multi-gated Acquisition (MUGA) scan with left ventricular ejection fraction (LVEF) < 45%
Show all 21Show fewer
- Prior receipt of salvage therapy, for relapsed or refractory cHL, including allogeneic or ASCT
- Prior receipt of investigational CD30.CAR-T cells
- Receiving any investigational agents or any tumor vaccines
- Receiving any live/attenuated vaccines
- Ongoing treatment with immunosuppressive drugs or chronic systemic corticosteroids
- Unresolved > Grade 1 non-hematologic toxicity associated with any prior treatments
- Previous history of known or suspected autoimmune disease within the past 5 years
- Active interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
- Evidence of human immunodeficiency virus (HIV) infection
- Evidence of active viral infection with hepatitis B virus (HBV)
- Evidence of active viral infection with hepatitis C virus (HCV)
- Active second malignancy or history of another malignancy within the last 3 years
- History of hypersensitivity reactions to murine protein-containing products or other product excipients
- Any allergic or adverse reaction to nivolumab, fludarabine, or bendamustine that precludes treatment with these agents
- History of a significant irAE from prior immune checkpoint inhibitor therapy
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
United States5 sites
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599
City of Hope National Medical Center
Duarte, California, 91010
Baylor College of Medicine
Houston, Texas, 77030
MD Anderson Cancer Center
Houston, Texas, 77030
University of Miami
Miami, Florida, 33136
About this study
Official title: Phase 1b Study Evaluating the Safety and Efficacy of Autologous CD30.CAR-T in Combination With PD-1 Checkpoint Inhibitor (Nivolumab) in Relapsed or Refractory Classical Hodgkin Lymphoma Patients After Failure of Frontline Therapy (ACTION)
This is a Phase 1b, multicenter, open-label, single arm study to evaluate the safety and efficacy of the combination therapy, CD30.CAR-T and the programmed cell death protein-1 (PD-1) checkpoint inhibitor, nivolumab, in patients aged 12 years of age and above with relapsed or refractory classical Hodgkin lymphoma (cHL) following failure of standard frontline therapy.
Read the detailed description
Upon successful leukapheresis to produce CD30.CAR-T cells, patients will enter the treatment phase of the study. Treatments will include 4 cycles of nivolumab and CD30.CAR-T infusion (preceded by lymphodepletion chemotherapy). Patients will then enter the post-treatment follow-up phase of the study, whereby patients will undergo either autologous stem cell transplant or continue to receive up to 6 additional treatment cycles of nivolumab. Patients will be followed for response assessments and safety monitoring until end of study (EOS); approximately 3 years after leukapheresis. Long-term follow-up will continue with additional safety monitoring and survival for up to 15 years after Leukapheresis.
- Being tested
- Nivolumab, Autologous CD30.CAR-T, Fludarabine, Bendamustine
- Keywords
- cHL
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NivolumabDrug
Also called Opdivo
Dose: 480 mg or 6 mg/kg Q4W
Autologous CD30.CAR-TDrug
Also called CD30-directed CAR-T cells
Dose: 2 x 10e8 cells/m2
FludarabineDrug
Also called Fludara
Dose: 30 mg/m2/day x 3 days
BendamustineDrug
Also called Bendeka, Treanda
Dose: 70 mg/m2/day x 3 days
| Study group | Role | What they receive |
|---|---|---|
| Nivolumab and CD30.CAR-T | Experimental | Study treatment will include 4 cycles of nivolumab and a single CD30.CAR-T infusion (preceded by lymphodepletion chemotherapy of Fludarabine and Bendamustine). Receives: Drug: Nivolumab; Drug: Autologous CD30.CAR-T; Drug: Fludarabine; Drug: Bendamustine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety of autologous CD30.CAR-T in combination with nivolumab
DLT
Measured: From first dose of nivolumab (Cycle 1) to end of nivolumab Cycle 4 (each cycle is 28 days)
Secondary outcomes (4)
Anti-tumor activity using CR rate of autologous CD30.CAR-T in combination with nivolumab
CR rate
Measured: Up to end of 10 weeks post-CD30.CAR-T treatment
Overall response rate
ORR
Measured: Through study completion, an average of 3 years from Leukapheresis
Duration of response
DOR
Measured: Through study completion, an average of 3 years from Leukapheresis
Progression-free survival
PFS
Measured: Through study completion, an average of 3 years from Leukapheresis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2022
- Study start25 Jul 2022
- Primary completion15 Dec 2025 (estimated)
- Study completion15 Dec 2037 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Classical Hodgkin LymphomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Upon successful leukapheresis to produce CD30.CAR-T cells, patients will enter the treatment phase of the study. Treatments will include 4 cycles of nivolumab and CD30.CAR-T infusion (preceded by lymphodepletion chemotherapy). Patients will then enter the post-treatment follow-up phase of the study, whereby patients will undergo either autologous stem cell transplant or continue to receive up to 6 additional treatment cycles of nivolumab. Patients will be followed for response assessments and safety monitoring until end of study (EOS); approximately 3 years after leukapheresis. Long-term follow-up will continue with additional safety monitoring and survival for up to 15 years after Leukapheresis.
- Masking
- None (open label)
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tessa Therapeutics
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Bristol-Myers Squibb
- Responsible party
- Sponsor
- Investigators
- Helen Heslop, MD, Principal investigator, Baylor College of MedicineSairah Ahmed, MD, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05352828
- Sponsor's protocol ID
- TESSCAR003
- Acronym
- ACTION
- Status last verified
- Mar 2023
- First submitted
- 8 Apr 2022
- Last updated
- 3 Apr 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase 1b Study Evaluating the Safety and Efficacy of Autologous CD30.CAR-T in Combination With PD-1 Checkpoint Inhibitor (Nivolumab) in Relapsed or Refractory Classical Hodgkin Lymphoma Patients After Failure of Frontline Therapy (ACTION)
- ClinicalTrials.gov ID
- NCT05352828
- Acronym / sponsor ID
- ACTION / TESSCAR003
- Keywords
- cHL
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Tessa TherapeuticsIndustry (pharma, biotech, devices)
- Collaborators
- Bristol-Myers Squibb
- Study start
- 25 Jul 2022 (actual)
- Primary completion
- 15 Dec 2025 (estimated)
- Study completion
- 15 Dec 2037 (estimated)
- First posted
- 29 Apr 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Phase 1b, multicenter, open-label, single arm study to evaluate the safety and efficacy of the combination therapy, CD30.CAR-T and the programmed cell death protein-1 (PD-1) checkpoint inhibitor, nivolumab, in patients aged 12 years of age and above with relapsed or refractory classical Hodgkin lymphoma (cHL) following failure of standard frontline therapy.
Detailed description
Upon successful leukapheresis to produce CD30.CAR-T cells, patients will enter the treatment phase of the study. Treatments will include 4 cycles of nivolumab and CD30.CAR-T infusion (preceded by lymphodepletion chemotherapy). Patients will then enter the post-treatment follow-up phase of the study, whereby patients will undergo either autologous stem cell transplant or continue to receive up to 6 additional treatment cycles of nivolumab. Patients will be followed for response assessments and safety monitoring until end of study (EOS); approximately 3 years after leukapheresis. Long-term follow-up will continue with additional safety monitoring and survival for up to 15 years after Leukapheresis.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Upon successful leukapheresis to produce CD30.CAR-T cells, patients will enter the treatment phase of the study. Treatments will include 4 cycles of nivolumab and CD30.CAR-T infusion (preceded by lymphodepletion chemotherapy). Patients will then enter the post-treatment follow-up phase of the study, whereby patients will undergo either autologous stem cell transplant or continue to receive up to 6 additional treatment cycles of nivolumab. Patients will be followed for response assessments and safety monitoring until end of study (EOS); approximately 3 years after leukapheresis. Long-term follow-up will continue with additional safety monitoring and survival for up to 15 years after Leukapheresis.
| Arm | Type | Receives |
|---|---|---|
| Nivolumab and CD30.CAR-T | Experimental | Drug: Nivolumab, Drug: Autologous CD30.CAR-T, Drug: Fludarabine, Drug: BendamustineStudy treatment will include 4 cycles of nivolumab and a single CD30.CAR-T infusion (preceded by lymphodepletion chemotherapy of Fludarabine and Bendamustine). |
Who may qualify
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (8 listed)
- Signed ICF
- Male or female patients who are 12 years of age and above
- Relapsed or refractory CD30+ cHL following failure of a standard frontline chemotherapy
- At least 1 lesion, which must be fluordeoxyglucose positron emission tomography (FDG-PET) avid and measurable by PET-CT scan
- Adequate laboratory parameters including hematologic, renal, hepatic, and coagulation function
Key exclusion criteria (21 listed)
- Evidence of lymphomatous involvement of the central nervous system (CNS)
- Presence of clinically relevant or active seizure disorder, stroke, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with central nervous system (CNS) involvement
- Symptomatic cardiovascular disease: Class III or IV according to the New York Heart Association (NYHA) Functional Classification
- Active uncontrolled bleeding or a known bleeding diathesis
- Inadequate pulmonary function defined as oxygen saturation by pulse oximetry < 90% on room air
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NivolumabAlso: OpdivoDose: 480 mg or 6 mg/kg Q4W | Drug | Nivolumab and CD30.CAR-T |
| Autologous CD30.CAR-TAlso: CD30-directed CAR-T cellsDose: 2 x 10e8 cells/m2 | Drug | Nivolumab and CD30.CAR-T |
| FludarabineAlso: FludaraDose: 30 mg/m2/day x 3 days | Drug | Nivolumab and CD30.CAR-T |
| BendamustineAlso: Bendeka, TreandaDose: 70 mg/m2/day x 3 days | Drug | Nivolumab and CD30.CAR-T |
Primary outcome
Safety of autologous CD30.CAR-T in combination with nivolumab
Time frame: From first dose of nivolumab (Cycle 1) to end of nivolumab Cycle 4 (each cycle is 28 days)
DLT
4 secondary outcomes
Anti-tumor activity using CR rate of autologous CD30.CAR-T in combination with nivolumab
Time frame: Up to end of 10 weeks post-CD30.CAR-T treatment
Overall response rate
Time frame: Through study completion, an average of 3 years from Leukapheresis
Duration of response
Time frame: Through study completion, an average of 3 years from Leukapheresis
Progression-free survival
Time frame: Through study completion, an average of 3 years from Leukapheresis
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Apr 2023.
- Individual participant dataSharing planned: No
Related trials for Classical Hodgkin Lymphoma
RecruitingPhase 3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Active, not recruitingPhase 2
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
Hodgkin Lymphoma
Active, not recruitingPhase 1
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL
Active, not recruitingPhase 3
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma
RecruitingPhase 1/2
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Hodgkin Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Helen Heslop, MD principal investigator
Baylor College of Medicine
Sairah Ahmed, MD principal investigator
M.D. Anderson Cancer Center
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Nivolumab, Autologous CD30.CAR-T and Fludarabine in people with Classical Hodgkin Lymphoma and Hodgkin Disease Refractory, run by Tessa Therapeutics at 5 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 3 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety of autologous CD30.CAR-T in combination with nivolumab (time frame: From first dose of nivolumab (Cycle 1) to end of nivolumab Cycle 4 (each cycle is 28 days)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2023.